GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 681-684

  Szabó, János ^a   Bartók, Katalin ^a   Krenács, Tibor ^b   Szepesváry, Zsolt ^a   Szende, Béla ^b  

^a Central Hospital of the Hungarian Army   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Androgen receptor; Carcinoma; GnRHR; Prostate

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; GONADORELIN RECEPTOR; GOSERELIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; MALE; NEEDLE BIOPSY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, LHRH; TREATMENT OUTCOME;

EID: 61449096819     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Shahani R, Fleshner NE, and Zlotta AR. Pharmacotherapy for prostate cancer: the role of hormonal treatment. Discov Med 39: 118-127, 2007.
2. Szende B, Lapis K, Redding TW et al: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat 14: 307-314, 1989.
3. Schally A and Comaru-Schally AM: Hypothalamic and other peptide hormones. In: Cancer Medicine. 4th ed. Holland JF, Frei E, III Bast RC Jr et al: (eds.) Baltimore (MD): Williams and Wilkins, pp. 1067-1086, 1997.
4. Qayum A, Gullick W, Clayton RC et al: The effect of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62: 96-99, 1990.
5. Dondi D, Limonta P, Moretti RM et al: Antiproliferative effects of luteinizing hormone-releasing hormone (LH-RH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LH-RH loop. Cancer Res 54: 4091-4095, 1994.
6. Damyanov C, Tzingliev B and Tobakov V: Treatment of an orchidectomized patient with hormone-refractory prostate cancer with LH-RH agonists. Eur Urol 40: 474-477, 2001.
7. Srkalovic G, Bokser L, Radulovic S et al: Receptors for luteinizing hormone-releasing hormone (LH-RH) in Dunning R-3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LH-RH antagonist SB-75. Endocrinology 127: 3052-3060, 1990.
8. Pinski J, Reile H, Halmos G et al: Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59: 51-55, 1994.
9. Halmos G, Arencibia JM, Serially AV et al: High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers. J Urol 163: 623-629, 2000.
10. Bahk JY, Hyun JS, Lee H et al: Expression of gonadotropin- releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 26: 259-264, 1998.
11. Limonta P, Moretti RM, Marelli MM et al: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size and signal transduction pathway. Endocrinology 140: 5250-5256, 1999.
12. Szabó J, Végh A, Rácz G et al: Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma. Urol Oncol 23: 399-401, 2005.
13. Comaru-Serially AM and Schally AV: Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Adv Drug Deliv Rev 28: 157-169, 1997.
14. Emons G, Müller V, Ortmann O et al: Effects of LH-RH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 65: 199-206, 1998.
15. Lee HJ and Chang C: Recent advances in androgen receptor action. Cell Molec Life Sci 60: 1613-1622, 2003.
16. Karakiewicz PI and Hutterer GC: Predicting outcomes in patients with urologie cancers. Curr Opin Support Palliat Care 3: 153-168, 2007.
17. Jin RJ, Lho Y, Connelly L et al: The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68: 6762-6769, 2008.